Navigation Links
Saladax Biomedical, Inc. Appoints Mark D. Myslinski as Chief Commercial Officer
Date:11/16/2012

BETHLEHEM, Pa., Nov. 16, 2012 /PRNewswire/ -- Saladax Biomedical, Inc., a privately held company developing and commercializing novel diagnostic assays to achieve the promise of personalized medicine for new and existing therapeutics, announced today that Mark D. Myslinski has been appointed senior vice president and chief commercial officer of the company.

Mr. Myslinski has nearly 30 years of life sciences and diagnostics industry experience with Fortune 100 and venture-backed startup organizations.  He was recently president and CEO of RedPath Integrated Pathology, Inc. where he and the team transformed the company from a research and market development focus to full commercialization of a novel molecular diagnostic assay in a Clinical Laboratory Improvements Amendments (CLIA) certified laboratory.

"Mark's extensive experience in diagnostics and his leadership within the life science community will be invaluable to Saladax as the company targets new markets for the commercialization of its MyCare assays," said Kevin Harter, president and CEO of Saladax.  "In particular, Mark's expertise will be critical as Saladax pursues the formation of a laboratory that meets CLIA standards."

Previous to Mr. Myslinski's time at RedPath Integrated Pathology, Inc., he served as vice president of evidence-based medicine at Ortho Clinical Diagnostics, Inc. and general manager, molecular and cellular diagnostics division of Veridex, LLC, both of which are Johnson & Johnson companies.

"I'm excited to join Saladax during this time of rapid growth with the formation of a CLIA certified laboratory at the company's headquarters and the continued expansion of its MyCare assays worldwide," said Mr. Myslinski.  "Saladax's solutions offer patients a means of personalized chemotherapy treatment by finding the optimal dose for each individual patient. This is very important to clinical outcomes by assuring the right dosage gets delivered to the patient in the most efficient manner."

About Saladax Biomedical, Inc.
Saladax Biomedical develops novel diagnostic assays for the practical delivery of personalized medicine.  Our proprietary line of MyCare™ assays improves the efficacy of existing drugs by optimizing the dose administered for each individual patient.  Saladax's initial focus is oncology, with a portfolio of 13 chemotherapy drug assays in various stages of development.  Three MyCare assays, My5-FU™, MyPaclitaxel™ and MyDocetaxel™, are currently offered to the oncology community in markets around the world. 

The company's MyCare technology platform is broad and flexible, enabling wide application in many therapeutic categories.  This technology also enables Saladax to serve as a valuable partner to pharmaceutical and biotechnology companies in the development of companion diagnostics (CDx), addressing multiple risks and challenges encountered in drug development.

The company was founded in 2004 and is headquartered in Bethlehem, Pennsylvania.  Saladax is ISO 13485:2003 certified.

Saladax Biomedical, Inc.
Adrienne Choma, Esq.
Sr. VP & Chief Operating Officer
achoma@saladax.com

Media Contact:
Tiberend Strategic Advisors, Inc.
212-827-0020
Andrew Mielach
amielach@tiberend.com
or
Claire Sojda
csojda@tiberend.com

 


'/>"/>
SOURCE Saladax Biomedical, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. NexGen Biomedical, Inc. Provides New Insights Into Jett Travoltas Seizure Related Death
2. Winner Medicals Special Committee Appoints Independent Financial Advisor and Retains Legal Counsel
3. Pro-Dex, Inc. Appoints Michael J. Berthelot Chief Executive Officer
4. Nephros Appoints John C. Houghton as President and Chief Executive Officer
5. Elsevier Appoints New President of Elsevier CPM Resource Center
6. GenWay Biotech Appoints New Vice President of Custom/OEM
7. Angeion Appoints Matthew S. Margolies as Executive Vice President - Global Sales
8. Althea Technologies Appoints Dr. Kristin DeFife, Director, Biologics Manufacturing And Jack Wright, VP, Sales and Marketing
9. Oxford BioTherapeutics Appoints Senior Industry Leader to Head its New Clinical Development Operations in Basel, Switzerland
10. Hill-Rom Appoints Alton Shader President of Hill-Rom North America
11. Synthetic Biologics Appoints Carol Reed, M.D., as Senior Vice President of Clinical & Regulatory Affairs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... June 24, 2016  Consumers have taken a ... have placed more emphasis on patient outcomes. ... programs in the pharmaceutical industry have evolved beyond ... pharmaceutical companies are focusing on becoming more patient-oriented ... products and services that improve health. ...
(Date:6/24/2016)... , June 24, 2016 ... Markets has announced the addition of the " ... offering. This ... and provides an updated review, including its applications in ... the total market, which includes three main industries: pharmaceutical ...
(Date:6/24/2016)... and SAN CLEMENTE, Calif. , June 24, ... -based mobile pulmonary function testing company, is now able to perform ... developed by ndd Medical Technologies , Inc. ... in hospital-based labs.  Thanks to ndd,s EasyOne PRO ® , ARL ... can get any needed testing done in the comfort of her ...
Breaking Medicine Technology:
(Date:6/25/2016)... , ... June 25, 2016 , ... "With 30 hand-drawn ... specific project," said Christina Austin - CEO of Pixel Film Studios. , ProHand ... all within Final Cut Pro X . Simply select a ProHand generator and ...
(Date:6/25/2016)... ... ... On Friday, June 10, Van Mitchell, Secretary of the Maryland Department of ... recognition of their exemplary accomplishments in worksite health promotion. , The Wellness at Work ... Symposium at the BWI Marriott in Linthicum Heights. iHire was one of 42 businesses ...
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is World ... with chronic pain and the benefits of holistic treatments, Serenity Recovery Center ... with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a disorder of the ...
(Date:6/24/2016)... ... 24, 2016 , ... Dr. Amanda Cheng, an orthodontist ... has extensive experience with all areas of orthodontics, including robotic Suresmile technology, ... , Micro-osteoperforation is a revolutionary adjunct to orthodontic treatment. It can be used ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... today at the Clinical Decision Making in Emergency Medicine conference in Ponte Vedra ... authored journal articles published in Emergency Medicine Practice and Pediatric Emergency ...
Breaking Medicine News(10 mins):